On the 2nd and 3rd June EFA representative Breda Flood participated at the European Alliance for Personalised Medicine (EAPM) Presidency Conference 'Smaller Members And Regions 
Together' (SMART), were she presented at the "Overcoming Barriers to Access and Understanding Value: Patient Access to Innovative Therapies" session. During her presentation, Breda explained that as a principle patients ' involvement should be a principle when adopting decisions influencing their health so that patients have the opportunity to be fully engaged from the start of the process of developing innovative treatments in order to be able to identify real unmet needs. In EFA's view, innovative treatments should be available to all on an equitable basis and this could be ensured with clear EU and national regulatory frameworks to ensure timely and equitable access for patients to personalised therapies. However, while innovative therapies and technologies are very important, many patients in Europe lack access or cannot afford the most basic medicines they need and Breda suggested not to forget that need.
A videoclip of the conference can be found here.